Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Quinidine versus verapamil in short-coupled idiopathic ventricular fibrillation
NL-OMON55988Phase 2Recruiting
- Sponsor
- Amsterdam University Medical Center
- Start
- Oct 2022
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 2, randomised, open-label trial of quinidine and verapamil in ventricular fibrillation (VF), idiopathic ventricular fibrillation (IVF) and Short-coupled torsades de pointes (scTdP) (2 arms), sponsored by Amsterdam University Medical Center. Primary endpoint: Freedom from sustained ventricular arrhythmia. Started Oct 2022; status: recruiting.
02
Drugs
quinidineverapamil
03
Conditions
ventricular fibrillation (VF)idiopathic ventricular fibrillation (IVF)Short-coupled torsades de pointes (scTdP)
Beyond the preview
Go deeper on NL-OMON55988.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NL-OMON55988.